Close

Mesothelin

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Product List Background Anti-Mesothelin CAR-T Services Anti-Mesothelin CAR-T In Vitro Assay ServicesAnti-Mesothelin CAR-T In Vivo Assay Services

Product List

Creative Biolabs provides various anti-Mesothelin-related products to support global customers’ projects, please feel free to contact us for further communication.

Background

Mesothelin encoded by MSLN, is a cell surface glycoprotein that is involved in kinds of important biological processes, such as cell proliferation, cell growth, cell adhesion, etc. Mesothelin overexpression is presented in several tumor types, including hematological malignancies, ovarian carcinomas, and lung adenocarcinomas. As the wide functions of mesothelin play, many researchers have been focused on the development of targeting mesothelin drugs, such as mesothelin antibodies, mesothelin ADC, and mesothelin CAR-T.

Schematic representation of Mesothelin-CART for associated diseases. Fig.1 Schematic representation of Mesothelin-CART for associated diseases.1

Associated Diseases

Anti-Mesothelin CAR-T Services

Anti-Mesothelin CAR-T In Vitro Assays

Anti-Mesothelin CAR-T Phenotype Characterization

CAR-T cell phenotype analysis provides a lot of intuitive and valuable information for development, including T cell subset distribution, CAR-T cell activity, and CAR-T cell exhaustion function. Creative Biolabs specializes in providing comprehensive phenotype characterization services for global customers to support CAR-T development.

Exhaustion phenotype analysis of TIM3, PD1, and LAG3 on anti-Mesothelin CART cells by flow cytometry. Fig.2 Exhaustion phenotype analysis of TIM3, PD1, and LAG3 on anti-Mesothelin CART cells by flow cytometry. (Red is target antibody, green is isotype control).1

Anti-Mesothelin CAR-T Expression Test

The evaluation of CAR expression is a key step in CAR-T development. The most common method is based on a flow cytometry approach with appropriate CAR detection reagents to assess. Creative Biolabs has successfully developed kinds of robust CAR expression reagents (target-specific reagents, linker-specific antibodies) for CAR-T cell analysis. Based on these sensitive reagents, we also provide comprehensive CAR expression testing services for global customers to accelerate the development of CAR-T.

CAR expression testing of anti-MSLN CART by flow cytometry. (Zhang, et al., 2021) Fig.3 CAR expression testing of anti-MSLN CART by flow cytometry. B). Flow analysis diagram of anti-MSLN CART proportion. C). Histogram of the MSLN-CAR positive subpopulation.1

Anti-Mesothelin CAR-T Cytokine Release Test

The cytokine-releasing response occurs in the incubation process of CART cells and target tumor cells, and these cytokines reflect the strength of CART cells’ response to the corresponding target cell to some extent. Leveraging Creative Biolabs’ expertise in cytokine array to evaluate the production of various cytokine in CART cells, customers will receive reliable cytokine profiling analysis data to support subsequent development studies.

Cytokine releasing analysis of IFN-g and TNF-a in anti-MSLN CART cells co-cultured with different target cells 24 hrs. Fig.4 Cytokine releasing analysis of IFN-g and TNF-a in anti-MSLN CART cells co-cultured with different target cells 24 hrs.1

Anti-Mesothelin CAR-T In Vitro Cytotoxicity Assay

The tumor-killing efficacy of CART is affected by its activation, expansion, and exhaustion processes. A robust and sensitive anti-tumor assay is a fundamental requirement for the translation of these CAR-T "living drugs". At Creative Biolabs, we offer various of CART in vitro cytotoxicity testing services, including chromium release-based assay, bioluminescence-based assay, flow cytometry-based assay, and RTCA assay.

Cytotoxicity evaluation of anti-MSLN CART cells against 3 solid tumor cell lines detected by RTCA assay. The red arrow indicated the time point at which effector cells are added. Fig.5 Cytotoxicity evaluation of anti-MSLN CART cells against 3 solid tumor cell lines detected by RTCA assay. The red arrow indicated the time point at which effector cells are added.1

Anti-Mesothelin CAR-T In Vivo Assays

Efficacy Test of Anti-Mesothelin CAR-T

For CART in vivo efficacy assessment, we provide a variety of animal models for customers to choose from, and we also provide optimized experimental design and efficacy evaluation tests to facilitate customers to get effective and reliable data most conveniently.

Efficacy Test of Anti-Mesothelin CAR-T in CDX Model

In vivo anti-tumor efficacy of anti-MSLN CART cells in HCT116 CDX model. (Zhang, et al., 2021) Fig.6 In vivo anti-tumor efficacy of anti-MSLN CART cells in HCT116 CDX model. B). The tumor size measurement of CDX model treated with anti-MSLN CART cells. C). Mice weight analysis of CDX model treated with anti-MSLN CART cells.1

Efficacy Test of Anti-Mesothelin CAR-T in PDX Model

In vivo anti-tumor efficacy of anti-MSLN CART cells in PDX model. (Zhang, et al., 2021) Fig.7 In vivo anti-tumor efficacy of anti-MSLN CART cells in PDX model. B). The tumor size measurement of PDX model treated with anti-MSLN CART cells. C). Mice weight analysis of PDX model treated with anti-MSLN CART cells.1

Toxicity Evaluation Anti-Mesothelin CAR-T

Unexpected toxicity responses are often presented in the CART development and therapy. Creative Biolabs is dedicated to providing toxicity evaluation services by various means, including on-target / off-tumor analysis, and neurologic toxicity analysis.

Treatment effect analysis of mice treated with anti-MSLN CART cells. Immunohistochemistry analysis of granzyme B in tumor sections. Fig.8 Treatment effect analysis of mice treated with anti-MSLN CART cells. Immunohistochemistry analysis of granzyme B in tumor sections.1

Reference

  1. Zhang, Qian, et al. "The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice." Molecular Therapy-Oncolytics 20 (2021): 556-568.
  • CAR Vector Products

  • TCR Vector Products

  • AbTCR Vector Products

  • TCR Cell Products

  • CAR Cell Products

  • CAR Viral Particles

  • Protein

  • TriCAR Vector Products

  • CAR-MA Vector Products

  • CAR-MA Cell Products

  • CAR Animal Cells

  • CAR mRNA

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
  • CAR Vector Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-LC086 Anti-Mesothelin (M21) h(41BB-CD3ζ) CAR, pCDCAR1 Human M21 Human scFv-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-LC087 Anti-Mesothelin (M22) h(41BB-CD3ζ) CAR, pCDCAR1 Human M22 Human scFv-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-LC088 Anti-Mesothelin (M23) h(41BB-CD3ζ) CAR, pCDCAR1 Human M23 Human scFv-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-LC089 Anti-Mesothelin (M24) h(41BB-CD3ζ) CAR, pCDCAR1 Human M24 Human scFv-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-YF116 Anti-Mesothelin (m912) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human m912 Human scFv-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YF157 Anti-Mesothelin (CBL-YF049) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human CBL-YF049 Humanized scFv-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YF158 Anti-Mesothelin (CBL-YF049) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBL-YF049 Humanized scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP074 Anti-Mesothelin (M13) h(CD28-CD3ζ) CAR, pCDCAR1 Human M13 Human scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-SB-LX0328 Anti-Mesothelin (Amatuximab) h(CD28-CD3ζ) CAR, pSBCAR1 Human Amatuximab Mouse scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
CAR-SB-LX0331 Anti-Mesothelin (Stamulumab) h(CD28-CD3ζ) CAR, pSBCAR1 Human Stamulumab Mouse scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
CAR-SB-LX0332 Anti-Mesothelin (H4H1657N2) h(CD28-CD3ζ) CAR, pSBCAR1 Human H4H1657N2 Mouse scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
CAR-SB-LX0333 Anti-Mesothelin (4B6-6) h(CD28-CD3ζ) CAR, pSBCAR1 Human 4B6-6 Mouse scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
CAR-SB-LX0334 Anti-Mesothelin (H4H1669P) h(CD28-CD3ζ) CAR, pSBCAR1 Human H4H1669P Mouse scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
CAR-SB-LX0335 Anti-Mesothelin (8D12-v2) h(CD28-CD3ζ) CAR, pSBCAR1 Human 8D12-v2 Mouse scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
CAR-SB-LX0336 Anti-Mesothelin (Ab237) h(CD28-CD3ζ) CAR, pSBCAR1 Human Ab237 Human scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
CAR-SB-LX0337 Anti-Mesothelin (HN1) h(CD28-CD3ζ) CAR, pSBCAR1 Human HN1 Human scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
CAR-SB-LX0338 Anti-Mesothelin (HN2) h(CD28-CD3ζ) CAR, pSBCAR1 Human HN2 Human scFv-CD28-CD3ζ Sleeping Beauty (SB) transposon T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.